Evolus Announces Participation in November Investment Conferences

Rhea-AI Summary

Evolus, Inc. (NASDAQ: EOLS) announced the participation of its management team in two investment conferences this November. The first event is the Stifel 2021 Virtual Healthcare Conference on November 16 at 2:40 pm ET. The second is the Evercore ISI 4th Annual HealthCONx Virtual Conference on November 30 at 7:30 am ET. Audio webcasts of both events will be available on Evolus' investor relations website for 90 days following the presentations. Evolus specializes in aesthetic products, including Jeuveau®, the first neurotoxin solely for aesthetics.

Positive

• Management participation in significant investment conferences may enhance visibility.
• Webcasts provide investors with easy access to company updates and discussions.

Negative

• None.

NEWPORT BEACH, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in two investment conferences in November.

	Event:	Stifel 2021 Virtual Healthcare Conference
	Date:	Tuesday, November 16, 2021
	Time:	2:40 pm ET
	Event:	Evercore ISI 4th Annual HealthCONx Virtual Conference
	Date:	Tuesday, November 30, 2021
	Time:	7:30 am ET

Audio webcasts of these events will be available on the investor relations section of Evolus’ website at www.evolus.com. Replays of the webcasts will be available for 90 days after the date of each presentation.

About Evolus, Inc.

Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. Approved in 2019 by the U.S. Food and Drug Administration, Jeuveau® (prabotulinumtoxinA-xvfs) is the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau^® is powered by Evolus’ unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at www.evolus.com.

Jeuveau^® is a registered trademark of Evolus, Inc.
Hi-Pure^™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Evolus, Inc. Contacts:

Investor/Media Contact:
David K. Erickson, Evolus, Inc.
Vice President, Investor Relations
Tel: 949-966-1798
Email: david.erickson@evolus.com

FAQ

What are the upcoming events for Evolus, Inc. in November 2021?

Evolus will participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, and the Evercore ISI 4th Annual HealthCONx Virtual Conference on November 30, 2021.

What time is the Stifel 2021 Virtual Healthcare Conference for Evolus?

The Stifel 2021 Virtual Healthcare Conference for Evolus is scheduled for November 16, 2021, at 2:40 pm ET.

When can I listen to the audio webcasts for Evolus' investment conferences?

Audio webcasts of Evolus' investment conferences will be available for 90 days after each event on their investor relations website.

What is Jeuveau® by Evolus, Inc.?

Jeuveau® is a neurotoxin exclusively dedicated to aesthetics, approved by the FDA in 2019, and manufactured using Hi-Pure™ technology.